Description:

Royal College of Surgeons in Ireland (RCSI) spin-out Pumpinheart is developing a transcatheter implantable heart pump to treat advanced stage Heart Failure with preserved Ejection Fraction (HFpEF aka Diastolic Heart Failure), an unmet medical need. The total addressable market of approximately 640k advanced HFpEF patients in the USA, Canada, UK and EU is estimated to be a $32B TAM, an $8B SAM and a $3.2B OAM. The goal is Left Atrial Pressure (LAP) reduction of 3 to 5 mmHg that is known to deliver therapeutic benefit. Preclinical trials have consistently demonstrated LAP reduction of two to three times the target.